DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma

Information source: Duke University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Glioblastoma; Gliosarcoma

Intervention: hydroxyurea (Drug); imatinib mesylate (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Duke University

Official(s) and/or principal investigator(s):
David A. Reardon, MD, Principal Investigator, Affiliation: Duke Cancer Institute


RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as hydroxyurea, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imatinib mesylate together with hydroxyurea may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving imatinib mesylate together with hydroxyurea works in treating patients with recurrent or progressive meningioma.

Clinical Details

Official title: A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Progression-free Survival at 6 Months

Secondary outcome:

Median Progression-free Survival (PFS)

Median Overall Survival (OS)

Objective Response Rate

Detailed description: OBJECTIVES: Primary

- Evaluate the activity of imatinib mesylate and hydroxyurea, as measured by 6-month

progression-free survival, in patients with recurrent or progressive meningioma. Secondary

- Evaluate the progression-free survival (PFS)

- Overall survival (OS),

- Objective response rate among patients treated with this regimen.

OUTLINE: This is an open-label study. Patients receive oral imatinib mesylate once or twice daily and oral hydroxyurea twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 21 patients will be accrued for this study.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.



- Histologically confirmed meningioma

- Recurrent or progressive disease after prior surgical resection

- Measurable disease by contrast-enhanced MRI

- Multifocal disease allowed

- No evidence of intratumor hemorrhage on pretreatment diagnostic imaging

- Stable postoperative grade 1 hemorrhage allowed

- No peripheral edema or central or systemic fluid collections ≥ grade 2 (e. g.,

pericardial effusion, pulmonary effusion, ascites) PATIENT CHARACTERISTICS:

- Karnofsky performance status 70-100%

- Absolute neutrophil count > 1,500/mm³

- Hemoglobin > 9 g/dL

- Platelet count > 100,000/mm³

- Potassium normal*

- Calcium normal*

- Magnesium normal*

- Phosphorus normal*

- alanine aminotransferase (AST) and alanine aminotransferase (ALT) < 2. 5 times upper

limit of normal (ULN)

- Bilirubin < 1. 5 times ULN

- Creatinine < 1. 5 times ULN OR creatinine clearance > 50 mL/min

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No excessive risk of bleeding, as defined by stroke within the past 6 months

- No active systemic bleeding (i. e., gastrointestinal bleeding or gross hematuria)

- No history of central nervous system (CNS) or intraocular bleeding or septic


- No concurrent severe and/or uncontrolled medical disease, including any of the


- Uncontrolled diabetes

- Congestive cardiac failure

- Myocardial infarction within the past 6 months

- Poorly controlled hypertension

- History of labile hypertension

- History of poor compliance with antihypertensive regimen

- Chronic renal disease

- Active uncontrolled infection requiring intravenous antibiotics

- No acute or chronic liver disease (i. e., hepatitis, cirrhosis)

- No HIV positivity

- No impairment of gastrointestinal function or disease that may significantly alter

the absorption of imatinib mesylate, including any of the following:

- Ulcerative disease

- Uncontrolled nausea

- Vomiting

- Diarrhea

- Malabsorption syndrome

- Bowel obstruction

- Inability to swallow tablets

- No other malignancy within the past 5 years except basal cell skin cancer or cervical

carcinoma in situ NOTE: *Unless correctable with supplements PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- Recovered from prior therapy

- More than 1 week since prior tumor biopsy

- More than 2 weeks since prior surgical resection

- Prior hydroxyurea allowed provided patient has not had progressive disease or

toxicity > grade 3

- No prior imatinib mesylate or other platelet-derived growth factor-directed therapy

- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)*

- Chemotherapeutic agents such as etoposide that are normally given at shorter

intervals allowed even if < 4 weeks from last prior dose of chemotherapy

- At least 4 weeks since prior radiotherapy*

- At least 1 week since prior biological, immunotherapeutic, or cytostatic drugs

- At least 2 weeks since prior investigational drugs

- No concurrent warfarin NOTE: *Unless there is unequivocal evidence of tumor


Locations and Contacts

Duke Cancer Institute, Durham, North Carolina 27710, United States
Additional Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Starting date: May 2005
Last updated: January 14, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017